+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.

Age: 40Years - 80YearsAll GendersPhase 3
281 locations
E

Actively Recruiting

Lung cancer is the leading cause of cancer-related death in the United States, and annual lung cancer screening with low-dose computed tomography LDCT has been shown to reduce mortality. However, many people who are eligible for screening based on U.S. Preventive Services Task Force guidelines do not undergo it. This study evaluates new strategies to improve lung cancer screening uptake among adults aged 50 to 80 with a significant smoking history. Participants will be randomly assigned to either enhanced usual care, which includes an educational brochure, or an intervention called Empower LCSCall. The Empower LCS intervention features patient education, provider notifications, patient reminders, and information about financial and community resources. Those who do not complete screening after the initial intervention may receive additional telephone navigation through the Call program to address barriers and assist with scheduling. Participants complete baseline and follow-up surveys at 4 and 8 months. Researchers will review electronic health records to assess discussions, orders, and completion of lung cancer screening. Some participants will also be invited to a one-time interview about their experiences. The study aims to assess the feasibility, acceptability, and preliminary effectiveness of the intervention to inform future efforts to improve equitable access to lung cancer screening.

Age: 50Years - 80YearsAll GendersPhase Not Applicable
57 locations
P

Actively Recruiting

This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.

Age: 18Years +All GendersPhase 3
306 locations
P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations
Z

Actively Recruiting

Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.

Age: 18Years +All GendersPhase 3
1190 locations